Distribution of the Pathogenicity Islands Markers (PAIs) in Uropathogenic E.coli Isolated from Children in Mofid Children Hospital


avatar Masoumeh Navidinia 1 , avatar Shahin Najar Peerayeh 1 , * , avatar Fatemeh Fallah 2 , avatar Bita Bakhshi 1 , avatar Saadat Adabian 1 , avatar Shadi Alimehr 2 , avatar Zari Gholinejad 2

Bacteriology Department of Medical Sciences Faculty, Tarbiat Modares University, [email protected], IR Iran
Pediatric Infections Research Center, Mofid Children Hospital, IR Iran

how to cite: Navidinia M, Najar Peerayeh S, Fallah F, Bakhshi B, Adabian S, et al. Distribution of the Pathogenicity Islands Markers (PAIs) in Uropathogenic E.coli Isolated from Children in Mofid Children Hospital. Arch Pediatr Infect Dis.1(2): 75-79. doi: 10.5812/pedinfect.9083.



Uropathogenic Escherichia coli (UPEC) is a causative agent of most of urinary tract infections (UTIs), which expresses a multitude of virulence factors.


The aim of this study was to investigate virulence associated characteristics characteristics in UPEC isolates derived from urine specimens, and to investigate the distribution of the pathogenicity islands virulence markers (PAIs) among the isolates in relation to their antibiotic susceptibility pattern.

Patients and Methods:

A total of 50 E.coli isolates were collected from patients with UTI during 2009 to August 2010. Biochemical and standard microbiological techniques were used to identify E.coli followed by screening for islands by polymerase chain reaction (PCR).


We found a high number of PAI markers such as PAI ICFT073, PAI IICFT073, PAI I536, PAI IV536, PAI II J96, and PAI II536 significantly associated with UPEC. High level of resistance to Aztreonam, Co-trimoxazole, Cefpodoxime, and Cefotaxime was found among the UPEC isolates.


This observation is of special value considering that the UPEC pathotype constitutes an emerging group of enteropathogens, particularly, in our county. Knowledge of the molecular details of Uropathogenic E.coli is useful to develop successful strategies for the treatment of urinary tract infection and complications associated with UTIs in human.

Full Text

Full text is available in PDF

© 2013, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.